DOI: http://dx.doi.org/10.18203/2349-3933.ijam20202104

Evaluation of adverse effect of second line ART in PL HIV patients treated by second line ART

Narendra Singh, Lalit Kumar, Desh Nidhi Singh

Abstract


Background: AIDS was first recognized in USA Subject whose viral load was very high more than 5000 copy and CD4 count remain below 100 for 6 months and decrease 50% of base line call as ART failure. There are grade 1, 2, 3 and 4 adverse effect can be seen .in treating of PL. HIV by ART2.

Methods: It was Single centre hospital based clinic pathological study and continuous longitudinal, prospective and retrospective , observational, in ART PLUS Centre considering of all patient on 1st line ART who are screened for treatment failure based on clinical, immunological and virological criterias as decided by SACEP from 2016 to 2018.

Results: This study shows increase in serum bilirubin from 5 to 13 in study subject and there was increase in no from 4 to 5 in subject of less than 9 Haemoglobin and in the group of 9 to 10 level Haemoglobin of subjects no. increase from 4 to 5 but more than 10 subject decrease from 110 to 108. Subject increase 6 to 10 of serum creatinine level >1.5mg /dl., This shows second line ART have adverse effect on liver , kidney and hematology. There is some adverse effect is seen as nausea, vomiting, headache, skin rash, abdominal pain and muscle pain, there was some serious adverse effect that required hospitalization.

Conclusions: Study show that ART2 have adverse effect on liver and kidney function and anaemia. Some general adverse effect seen that also required treatment.


Keywords


Art, CD4, Human immunodificiency syndrome, SACEP

Full Text:

PDF

References


Chauhan NS, Shah SP, Desai MK, Shah A. A safety analysis of different drugs regimens in immunodeficiency virus-positive patient. 201839(2):84-90.

Karnani RK, Manoz SK, Kamdar S. A comparison of adverse drugs events profile of two ART regimens consisting Zadivudine. Plus, La ivudine verses Stavudine plus Lamuvudine in comparison with Nevirapine in adult HIV /AIDS patients in atertiary care hospital. 2015; 2(3):120.

Chandwani A, Shuter J. Lopinavir/Ritonavir in the treatment of HIV-3 infection. a review; Therapeutics and clinical risk management. 2008 4(5);1023-33.

Vaghani SV, Gagiya AK, Shukla DK, Patel VP. Adeverse effect of antiretroviral treatments atertiary care hospital in India, a prospective observational study. Int J Res Med Sci. 2013;1:101-3.

Pindari JA, Santos J, Kader AA, Palacios R, Camacho RA, Kisano F. Liver toxicity of antiretroviral combinations including Atanzanavir/ritonavir in patients coinfected with HIV and Hepatitis Virus J.A. Antimicrob Chemother. 2008;61(4):925-32.

Palacios R, Vergara S, Rivero A, Aguilar I, MacĂ­as J, Camacho A. Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir. HIV clinical trials. 2006 Dec 1;7(6):319-23.

Wikman P, Safont P, Palacio MD, Moreno A, Moreno S, Casado JL. The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients. Nephrology Dialysis Transplantation. 2013 Aug 1;28(8):2073-81.

Patel D, Desai M, Shah AN, Dikshit RK. Early outcome of second line antiretroviral therapy in treatment-experienced human immunodeficiency virus positive patients. Perspect Clin Resea. 2013 Oct;4(4):215.